u/CaptainMilligram

WHAT IS IT?

GLOW is a precision-formulated regenerative peptide blend combining three of the most researched healing and tissue repair compounds available: GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper), TB-500 (Thymosin Beta-4), and BPC-157 (Body Protection Compound 157). Each compound targets a distinct phase and pathway of the healing and regeneration cascade, and together they produce a synergistic effect on tissue repair, skin rejuvenation, inflammation control, and collagen synthesis that none of the three achieves as completely alone. GLOW is designed for individuals who want comprehensive, inside-out regeneration from a single coordinated protocol.

WHO IS IT FOR?

Ideal candidates:

• Athletes and active individuals dealing with acute or chronic injuries to tendons, ligaments, muscles, or joints who want the most comprehensive peptide healing protocol available
• Those recovering from surgery, significant physical trauma, or procedures where accelerated tissue repair and reduced scarring are priorities
• Individuals focused on skin health, anti-aging, and aesthetic improvement including improved skin density, collagen restoration, and reduced visible signs of aging
• People with chronic inflammation, slow recovery between training sessions, or systemic tissue degradation associated with aging or overtraining
• Those running GLP-1 compounds (Semaglutide, Tirzepatide, Retatrutide) who want gut lining support and systemic recovery alongside their fat loss protocol
• Biohackers and longevity-focused individuals who want foundational regenerative coverage addressing wound healing, collagen synthesis, cell migration, and gene expression remodeling simultaneously

Not recommended for:

• Active malignancy or history of cancer; all three compounds promote angiogenesis and cell growth which carries theoretical concerns in oncology contexts
• Pregnancy or breastfeeding
• Individuals with Wilson's disease or copper metabolism disorders due to the GHK-Cu component

PRIMARY USE CASE

GLOW's primary use case is comprehensive tissue regeneration and healing through three complementary and non-redundant biological mechanisms operating simultaneously. The blend is specifically designed around the fact that tissue repair is a multi-phase, multi-pathway process that single compounds cannot fully address alone.

BPC-157 provides structural reattachment and vascular support, TB-500 coordinates cellular migration and prevents fibrosis, while GHK-Cu offers antioxidant protection and reduces inflammatory damage. Together they address the full healing cascade from initial injury response through tissue remodeling, making GLOW particularly well-suited for complex injuries, post-surgical recovery, and skin regeneration protocols where depth and completeness of healing matter as much as speed.

Secondary benefits include skin quality improvements from GHK-Cu's collagen and extracellular matrix stimulation, systemic flexibility and range of motion improvements from TB-500's actin regulation, gut lining protection and repair from BPC-157's gastric origin activity, and broad anti-aging effects from GHK-Cu's gene expression remodeling across hundreds of genes simultaneously.

MECHANISM OF ACTION

Each compound in GLOW contributes a distinct and complementary mechanism targeting a different phase of the regenerative cascade:

GHK-Cu: Collagen Synthesis and Gene Expression Remodeling GHK-Cu delivers bioavailable copper to tissue repair sites, activating lysyl oxidase for collagen and elastin crosslinking, stimulating fibroblasts to produce collagen types I, III, and IV, and upregulating the expression of genes associated with tissue repair, antioxidant defense, and skin regeneration. It is the structural rebuilding and gene-level anti-aging component of the blend.

TB-500: Systemic Cell Migration and Antifibrotic Activity TB-500 binds to actin to enhance cell mobility and migration to injury sites throughout the body, promotes angiogenesis for improved blood supply to damaged tissue, and consistently demonstrates antifibrotic activity that preserves functional tissue architecture during healing. It is the systemic coordination and anti-scarring component of the blend.

BPC-157: Localized Repair and Anti-Inflammatory Signaling BPC-157 stimulates new blood vessel formation at injury sites through VEGF and nitric oxide pathway modulation, promotes tendon, muscle, gut, and connective tissue healing through fibroblast activation, and provides potent localized anti-inflammatory effects. It is the targeted repair and vascular restoration component of the blend.

The Combined Effect The three mechanisms address different but overlapping phases of tissue repair. BPC-157 initiates and drives the early vascular and inflammatory response. TB-500 coordinates cell migration and prevents the fibrotic scarring that impairs functional recovery. GHK-Cu rebuilds the extracellular matrix and remodels gene expression for lasting structural restoration. The result is faster wound closure, stronger tissue regeneration, and reduced fibrosis compared to what any single compound produces in isolation.

DOSING PROTOCOL

GLOW is administered via subcutaneous injection once daily. The standard vial contains 70mg of the blend with a ratio of approximately 50mg GHK-Cu, 10mg TB-500, and 10mg BPC-157, reflecting GHK-Cu's lower per-microgram potency relative to the other two compounds.

• Route: Subcutaneous injection
• Injection site: Lower abdomen, thigh, or upper arm, rotating sites systematically
• Frequency: Once daily
• Timing: No specific timing requirement; consistent daily dosing at the same time is recommended

Reconstitution:

• Add 3.0mL of bacteriostatic water to the 70mg vial
• This produces a concentration of 23.3mg/mL
• Lower daily dose: 2,330mcg (2.33mg) total blend per injection, drawn to the 10-unit (0.10mL) mark on an insulin syringe
• This delivers approximately 1.7mg GHK-Cu, 0.33mg TB-500, and 0.33mg BPC-157 per injection
• Standard daily dose: 3,500mcg (3.5mg) total blend per injection, drawn to the 15-unit (0.15mL) mark on an insulin syringe
• This delivers approximately 2.5mg GHK-Cu, 0.5mg TB-500, and 0.5mg BPC-157 per injection

Cycle guidance:

• Standard cycle: 4 weeks of daily injections followed by a 2 to 4-week rest period
• Assess progress before considering a subsequent cycle
• For acute injuries, a full 4-week loading cycle is recommended before evaluating response
• For ongoing maintenance and anti-aging applications, some users run GLOW continuously at the standard dose with periodic assessment breaks

WHAT TO EXPECT: TIMELINE

Days 1 to 7: Reduced inflammation and pain at injury sites are often among the first noticeable effects, driven primarily by BPC-157's early anti-inflammatory activity. Some users report improved gut comfort and reduced systemic inflammation within the first week. Skin hydration and texture may show early subtle improvements from GHK-Cu.

Weeks 2 to 4: Measurable improvements in mobility, flexibility, and injury function become apparent as TB-500's cell migration and antifibrotic activity compounds alongside BPC-157's vascular restoration. Skin firmness and texture improvements become more visible. Recovery between training sessions improves noticeably as systemic inflammation decreases.

Weeks 4 to 8: Significant structural healing progress across all targeted tissues. The combination of angiogenesis, cell migration, collagen synthesis, and gene expression remodeling produces cumulative benefits that become increasingly apparent. Chronic injuries that have been resistant to other interventions often show meaningful progress. Skin quality improvements including reduced fine lines, improved elasticity, and enhanced overall complexion are well established by this stage.

Weeks 8 to 12: Most acute injuries should be substantially resolved with consistent dosing and appropriate rehabilitation. Skin regeneration and collagen restoration continue to accumulate. Flexibility and range of motion gains from TB-500's actin regulation are often a standout result by this point. GHK-Cu's gene expression remodeling continues to produce anti-aging benefits that extend beyond the visible skin improvements.

STACK COMPATIBILITY

Pairs well with:

• Tesamorelin or CJC-1295 (No DAC) with Ipamorelin for a complete anti-aging and recovery protocol layering GH optimization on top of GLOW's tissue-level regeneration
• Epithalon for a comprehensive longevity protocol targeting telomere lengthening and pineal function alongside GLOW's tissue and skin regeneration
• GLP-1 compounds (Semaglutide, Tirzepatide, Retatrutide) where BPC-157 within GLOW provides gut lining support during titration-related GI stress
• Microneedling for dramatically enhanced GHK-Cu penetration and follicle stimulation; applying GHK-Cu topically immediately after microneedling amplifies local delivery significantly
• Collagen peptides, vitamin C, and adequate dietary protein to support the connective tissue synthesis that GLOW's compounds are actively driving

Use with caution:

• NSAIDs and corticosteroids; these blunt inflammatory pathways that BPC-157 and TB-500 partially work through, though BPC-157 also independently counteracts NSAID-induced gut damage
• Anticoagulants given the angiogenic activity of multiple compounds in the blend
• High-dose zinc supplementation; zinc and copper compete for absorption and may reduce GHK-Cu efficacy

Avoid:

• Use during active cancer treatment without oncologist approval given the cell growth and angiogenic promoting properties across all three compounds
• Freezing the reconstituted solution; this degrades peptide structure and significantly reduces potency
• Injecting at the same site repeatedly; systematic rotation is essential for maintaining tissue health at injection sites over a 4-week daily cycle

SIDE EFFECTS

GLOW's side effect profile reflects the combined activity of all three compounds, each of which individually carries an excellent tolerability record. Serious adverse effects are extremely rare.

• Injection site irritation: the most common practical concern with daily subcutaneous injection; mild redness or discomfort that resolves without intervention and is minimized by consistent site rotation
• Mild nausea: occasionally reported, typically mild and early in the cycle; more common in individuals sensitive to BPC-157
• Fatigue or lethargy: occasionally reported in the first 1 to 2 days after each injection during the early loading phase; generally resolves quickly and is considered by many users as a sign of active healing response
• Headache: occasionally reported, typically mild and transient in the first week
• Temporary skin discoloration: a mild bluish or greenish tint at the injection site immediately following administration from the copper component of GHK-Cu; resolves within minutes as the peptide is absorbed
• Vivid dreams: occasionally reported, consistent with BPC-157's dopaminergic modulation; generally benign

No significant toxicity has been observed in preclinical research for any of the three individual compounds. The combined GLOW formulation has not been evaluated in formal human clinical trials but individual component safety profiles are among the most favorable in the peptide category.

STORAGE AND HANDLING

• Unreconstituted (lyophilized powder): Store frozen or at 2 to 8°C (refrigerated). Stable for up to 24 months under proper conditions. Protect from light and moisture.
• Reconstituted solution: Refrigerate at 2 to 8°C. Do not freeze once reconstituted.
• Keep away from direct light at all stages; all three compounds have some light sensitivity in solution.
• Do not shake the vial; gently swirl or roll until fully dissolved when reconstituting.
• Label the vial clearly with the reconstitution date and discard after 4 weeks regardless of remaining volume.
• Use insulin syringes of 30 or 50 units for improved readability at the standard 10-unit dose; larger syringes make accurate measurement more difficult at this volume.
• Practice aseptic technique at every injection; clean both the vial stopper and the injection site with separate alcohol swabs and allow to air dry completely before proceeding.

DISCLAIMER

The information in this guide is intended for educational purposes only and does not constitute medical advice. 

WHAT IS IT?

Melanotan II (MT-2) is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide derived from proopiomelanocortin (POMC) that regulates skin pigmentation, sexual function, appetite, and energy balance through the melanocortin receptor system. Originally developed at the University of Arizona as a potential tanning agent, it was found to produce a broad range of additional effects through its non-selective activation of multiple melanocortin receptor subtypes, most notably dramatically enhanced libido and sexual function alongside its pigmentation and appetite-suppressing effects.

WHO IS IT FOR?

Ideal candidates:

• Individuals seeking enhanced skin tanning response with reduced UV exposure requirement
• Those dealing with sexual dysfunction including reduced libido, erectile dysfunction, or arousal difficulties
• People interested in appetite suppression and metabolic support as part of a body composition protocol
• Men and women looking for a multi-effect compound addressing tanning, sexual health, and body composition simultaneously
• Those who have used MT-2 via injection previously and prefer the convenience and reduced discomfort of intranasal delivery

Not recommended for:

• Individuals with a personal or family history of melanoma or other skin cancers given MT-2's stimulation of melanocyte activity
• Those with numerous atypical moles or high melanoma risk profiles
• Pregnancy or breastfeeding
• Individuals prone to nausea who have not started at a conservative dose; nausea is the most common and dose-limiting side effect
• People seeking a pure tanning agent without the libido and appetite effects; MT-2 is non-selective and its other effects cannot be isolated

PRIMARY USE CASE

MT-2's primary use case spans three interconnected areas driven by its broad melanocortin receptor activation: skin pigmentation enhancement, sexual function improvement, and appetite suppression.

For tanning, MT-2 stimulates melanogenesis by activating MC1 receptors on melanocytes, increasing eumelanin production and producing a deeper, longer-lasting tan with significantly less UV exposure than would otherwise be required. This is its original intended application and remains one of its most sought-after effects.

For sexual function, MT-2's activation of MC3 and MC4 receptors in the central nervous system produces potent pro-erectile and libido-enhancing effects in both men and women. In men, spontaneous erections are a commonly reported effect even at low doses, and the compound has demonstrated efficacy for psychogenic and organic erectile dysfunction in clinical research. In women, enhanced arousal, lubrication, and sexual motivation are the primary reported effects.

For appetite and body composition, MC4 receptor activation in the hypothalamus suppresses appetite and increases energy expenditure, contributing to fat loss and reduced caloric intake as secondary effects of the compound's broader receptor activity.

MECHANISM OF ACTION

MT-2 works through non-selective activation of the melanocortin receptor family, with each receptor subtype contributing a distinct set of effects:

MC1 Receptor: Pigmentation and Melanogenesis MC1 receptors are expressed on melanocytes in the skin. MT-2 activation of MC1 stimulates the production and release of eumelanin, the dark brown pigment responsible for tanning. This increases baseline skin pigmentation and dramatically enhances the tanning response to UV exposure, producing a deeper and more rapid tan than UV alone would generate.

MC3 and MC4 Receptors: Sexual Function and Libido MC3 and MC4 receptors in the hypothalamus and limbic system mediate MT-2's sexual effects. MC4 activation in particular drives pro-erectile signaling in men through central nervous system pathways independent of the peripheral vascular mechanisms targeted by PDE5 inhibitors like Viagra, making MT-2 mechanistically distinct and potentially effective in cases where PDE5 inhibitors alone are insufficient. In women the same central pathways produce enhanced arousal and sexual motivation.

MC4 Receptor: Appetite Suppression and Energy Expenditure MC4 receptor activation in the hypothalamic arcuate nucleus suppresses appetite signaling and increases sympathetic nervous system activity, raising metabolic rate and reducing food intake. These effects are the basis for ongoing research into melanocortin system targeting for obesity treatment and contribute to MT-2's body composition benefits.

MC3 and MC5 Receptors: Ancillary Effects MC3 and MC5 receptor activity contributes to MT-2's effects on inflammation, immune modulation, and sebaceous gland function. These are secondary to its primary applications but contribute to the compound's broad physiological footprint.

RECONSTITUTION

This vial contains 10mg of lyophilized MT-2 powder. Before use, the powder must be reconstituted with bacteriostatic water (BAC water).

Recommended reconstitution volume: 2mL of BAC water produces a concentration of 5mg/mL (5000mcg/mL), which is a practical concentration for standard insulin syringe dosing.

Step 1: Allow the vial to reach room temperature before reconstituting.

Step 2: Using a sterile syringe, draw 2mL of BAC water.

Step 3: Insert the needle through the rubber stopper of the MT-2 vial and inject the BAC water slowly down the inside wall of the vial. Do not inject directly onto the powder or force the liquid in rapidly.

Step 4: Do not shake the vial. Gently swirl or allow it to dissolve on its own. The powder should dissolve completely within a few minutes.

Step 5: Once reconstituted, the solution should appear clear and colorless. Do not use if the solution appears cloudy, discolored, or contains visible particulate matter.

At 2mL total volume and 5mg/mL concentration, each 0.1mL (10 units on an insulin syringe) delivers 500mcg. This makes dose measurement straightforward with standard U-100 insulin syringes.

DOSING PROTOCOL

Frequency: Daily during loading, transitioning to maintenance or as-needed dosing

Timing: Evening dosing is recommended for most users as nausea and facial flushing, the most common side effects, are more manageable during sleep

Loading Phase: Weeks 1 to 2

The goal of the loading phase is to build baseline melanin saturation and establish the enhanced tanning response before UV activation begins.

Days 1 to 3: 0.25mg daily

Days 4 to 7: 0.5mg daily

Week 2: 0.5 to 1mg daily

Begin conservatively and allow nausea tolerance to develop before increasing. Most users find side effects are well managed by the end of Week 1.

Tanning Phase: Weeks 3 to 6

With baseline melanin established, UV exposure is introduced to drive active pigmentation development.

Dose: 0.5 to 1mg on tanning days, administered 30 to 60 minutes before UV exposure

Frequency: 2 to 4 tanning sessions per week

Adjust dose and UV duration based on skin type and individual darkness response. Lighter skin types should start with shorter UV sessions and lower doses within the range, increasing gradually as tolerance and pigmentation develop. MT-2 significantly amplifies the tanning response, so UV exposure that previously produced minimal color will now produce substantially more.

Maintenance Phase: Weeks 7 to 12

Once target pigmentation is achieved, daily dosing is no longer required. The goal shifts to sustaining color with minimal compound use.

Dose: 0.25 to 0.5mg, 2 to 3 times per week

Minimal UV exposure is still beneficial for maintaining depth of color but frequent sessions are not necessary at this stage.

Pigmentation gained through MT-2 fades more slowly than UV-only tans and can persist for several weeks after cessation. Some users maintain year-round pigmentation with periodic low-dose maintenance and minimal UV exposure.

Sexual Function Dosing (as needed, outside of tanning protocol):

500 to 1000mcg administered 1 to 2 hours before anticipated use

Effects typically onset within 45 to 90 minutes of subcutaneous administration

Lower doses are often sufficient for sexual function effects than for full tanning loading

WHAT TO EXPECT: TIMELINE

Days 1 to 5: Facial flushing, warmth, and mild nausea in the 30 to 90 minutes following administration are the most commonly reported initial effects. Spontaneous erections in men and increased arousal in women are often reported from the first or second dose even before visible tanning begins. Appetite suppression may be noticeable early.

Days 5 to 14: With regular dosing and UV exposure, visible tanning begins to develop. The tan produced by MT-2 tends to appear warmer and deeper than UV-only tanning, with a particular tendency to develop on areas that typically tan poorly. Sexual effects are well established by this point and consistent with each dose. Nausea typically diminishes significantly as tolerance develops.

Weeks 2 to 4: Pigmentation continues to deepen with ongoing UV activation. Many users achieve their desired tan level within 3 to 4 weeks of consistent loading. Facial flushing and nausea are typically minimal by this stage. Body composition effects from appetite suppression become more apparent with consistent use.

Weeks 4+: Transition to maintenance dosing to sustain pigmentation. Tanning response to UV remains significantly enhanced compared to baseline even on maintenance doses. Sexual function benefits persist with ongoing use.

Pigmentation gained through MT-2 fades more slowly than UV-only tans and can persist for several weeks after cessation. Some users maintain year-round pigmentation with periodic low-dose maintenance and minimal UV exposure.

STACK COMPATIBILITY

Pairs well with:

• PT-141 (Bremelanotide) for enhanced and more targeted sexual function effects; PT-141 is a metabolite of MT-2 that acts more selectively on sexual function receptors with less nausea
• Semaglutide or Tirzepatide for a comprehensive appetite suppression and body composition protocol layering GLP-1 mechanisms on top of MC4-mediated appetite reduction
• BPC-157 for systemic anti-inflammatory and recovery support alongside MT-2's broader physiological activity
• Tesamorelin for a complete body composition protocol combining visceral fat reduction with appetite suppression and metabolic support

Use with caution:

• PDE5 inhibitors (Viagra, Cialis); MT-2's central pro-erectile mechanism combined with PDE5 inhibition's peripheral vasodilation can produce exaggerated erectile response and potential cardiovascular strain
• Antihypertensive medications; MT-2 can produce transient blood pressure changes that may interact with blood pressure management
• Other appetite-suppressing compounds; combined appetite suppression can lead to insufficient caloric and protein intake

Avoid:

• Use without sun protection awareness; MT-2 dramatically increases UV sensitivity and tanning response; uncontrolled UV exposure during loading significantly increases sunburn risk if dose and UV exposure are not managed proportionally
• Use in individuals with high melanoma risk or numerous atypical nevi without dermatological clearance
• Storing or using degraded solution; MT-2 degrades relatively quickly in solution and using degraded product increases unpredictability of effects

SIDE EFFECTS

MT-2 has a well-documented side effect profile from both clinical research and extensive community reporting. Most adverse effects are dose-dependent and manageable with conservative titration.

• Nausea: the most commonly reported side effect, occurring in the 30 to 90 minutes following administration, particularly during the loading phase; typically diminishes significantly with continued use as tolerance develops
• Facial flushing and warmth: common and typically transient, lasting 30 to 60 minutes post-dose; evening dosing minimizes the practical impact
• Spontaneous erections: a commonly reported effect in men, particularly at higher doses; can be unexpected and inconvenient outside of intended use contexts; dose reduction manages this
• Fatigue or yawning: frequently reported in the hours following administration, likely related to central melanocortin activity; evening dosing is largely preferable for this reason
• Darkening of existing moles and freckles: MT-2's melanocyte stimulation affects all pigmented lesions, not just general skin tone; existing moles should be monitored and any changes assessed by a dermatologist
• Appetite suppression beyond the intended effect: can lead to insufficient caloric intake if not actively managed
• Increased libido beyond the intended effect: some users find the libido-enhancing effects more pronounced than desired at higher doses; dose reduction resolves this
• Hypertension: transient blood pressure increases have been reported; individuals with pre-existing cardiovascular conditions should monitor blood pressure during use
• Stretch marks or existing scars darkening: areas with existing hyperpigmentation or scarring may darken disproportionately

STORAGE AND HANDLING

• Prepared nasal solution: Refrigerate at 2 to 8°C at all times. MT-2 in solution is more susceptible to degradation than many other peptides; consistent cold storage is particularly important.
• Do not freeze the prepared solution.
• Keep away from direct light at all times; MT-2 is light-sensitive in solution and exposure accelerates degradation.

DISCLAIMER

The information in this guide is intended for educational purposes only and does not constitute medical advice. 

WHAT IS IT?

Tesamorelin is a synthetic peptide that signals your own pituitary gland to produce and release more growth hormone, keeping the process natural and pulsatile rather than introducing exogenous GH directly.

WHO IS IT FOR?

Ideal candidates:

• Men and women looking to reduce stubborn visceral fat (the deep abdominal fat surrounding organs)
• Individuals with declining GH levels due to age or lifestyle
• Those seeking improved body composition without direct GH or anabolic compounds
• People interested in cognitive, cardiovascular, and metabolic support alongside physique goals

Not recommended for:

• Active malignancy or history of cancer
• Pregnancy or breastfeeding
• Known hypersensitivity to GHRH analogs
• Individuals with pituitary disorders or damage

PRIMARY USE CASE

Tesamorelin's primary and most clinically validated use is visceral fat reduction. It is one of the only compounds with direct FDA approval for excess visceral adipose tissue (VAT), making it uniquely well-supported compared to most peptides on the market.

Secondary benefits include improved body composition, lean mass support, cognitive enhancement, and favorable changes to lipid and cardiovascular markers.

MECHANISM OF ACTION

Rather than introducing growth hormone directly, tesamorelin works upstream, triggering your body's own production through a natural cascade:

Step 1: GHRH Receptor Binding Tesamorelin binds GHRH receptors in the pituitary gland, signaling it to synthesize and release endogenous GH.

Step 2: Pulsatile GH Secretion The pituitary responds with natural, pulsatile GH release, preserving the body's normal hormonal rhythm and feedback loops.

Step 3: IGF-1 Upregulation Rising GH levels signal the liver to produce IGF-1, the primary mediator responsible for GH's downstream tissue-level effects.

Step 4: Lipolysis and Protein Synthesis GH and IGF-1 together promote visceral fat breakdown and enhance protein synthesis, supporting body composition and tissue repair.

DOSING PROTOCOL

• Dose: 1-2mg
• Frequency: Once daily
• Timing: At bedtime (aligns with natural GH pulse)
• Route: Subcutaneous injection
• Injection site: Abdominal area, rotating sites
• Reconstitution: Mix lyophilized powder with provided bacteriostatic water immediately before use

No titration required. Begin at the full 2mg dose from day one.

WHAT TO EXPECT: TIMELINE

Weeks 1 to 2: Improved sleep quality and recovery are often the first noticeable effects as GH begins to rise.

Weeks 3 to 6: Energy, mood, and general sense of wellbeing typically improve. Early changes in water retention and body composition may begin.

Weeks 6 to 12: Measurable reductions in visceral fat become apparent. Body composition improvements including less VAT and improved muscle definition are typically visible by week 12 with proper diet and training.

Weeks 12+: Continued fat loss and lean mass improvements. Clinical studies show the most significant VAT reductions occur between 3 to 6 months of consistent use.

Results vary based on diet, training, sleep, and baseline GH levels. Bloodwork (IGF-1) at 6 to 8 weeks is recommended to confirm response.

STACK COMPATIBILITY

Pairs well with:

• BPC-157 / TB-500 for complementary healing and recovery support
• CJC-1295 (without DAC) for enhanced GH pulse
• Ipamorelin, a GHRP that works synergistically to amplify GH release
• GLP-1 agonists (e.g. Semaglutide) for aggressive fat loss protocols

Use with caution:

• Direct GH (e.g. HGH) due to redundant mechanism and increased risk of adverse events
• High-dose insulin; monitor glucose response carefully

Avoid:

• Combining with other GHRH analogs simultaneously

SIDE EFFECTS

Generally well-tolerated with a strong clinical safety profile. Side effects are typically mild and transient.

• Injection site redness/itching: common in early weeks, usually resolves as the body adjusts
• Mild joint or muscle pain: occasional, related to fluid shifts from rising GH and typically subsides
• Peripheral edema: occasional swelling in hands/feet; monitor and reduce dose if persistent
• Headache: uncommon, often resolves after the first 1 to 2 weeks

STORAGE AND HANDLING

• Unreconstituted (lyophilized powder): Store at 2 to 8°C (refrigerated). Stable for up to 24 months when stored correctly. Can tolerate room temperature for short periods during shipping.
• Reconstituted: Must be refrigerated at 2 to 8°C. Do not freeze once reconstituted.
• Keep away from direct light and heat.
• Do not shake. Gently swirl when mixing to avoid degrading the peptide.

DISCLAIMER

The information in this guide is intended for educational purposes only and does not constitute medical advice